Dunbar G C
SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK.
Pharmacology. 1995 Sep;51(3):137-44. doi: 10.1159/000139327.
In a meta-analysis of ten studies in elderly patients, paroxetine (n = 387) was as effective an antidepressant as active controls (amitriptyline n = 110; clomipramine n = 109; doxepin n = 102; mianserin n = 28). The change over 5-6 weeks of therapy, on the Hamilton Depression Rating Scale, was significantly better with paroxetine compared with active controls. A similar advantage was seen when the responder rate was considered. Adverse events were less frequent and less severe with paroxetine treatment, especially anticholinergic adverse events. Paroxetine was effective in treating anxiety symptoms associated with depression, yet caused significantly less sedation compared with active controls. There was little difference in the overall safety profiles seen between the paroxetine and active control groups. However, data are available indicating reduced cardiotoxicity for paroxetine and a beneficial effect on suicidal thoughts. Overall, the results indicate paroxetine is an alternative first-line therapy to these older antidepressants and should be considered when treating elderly patients.
在一项针对老年患者的十项研究的荟萃分析中,帕罗西汀(n = 387)作为抗抑郁药与活性对照药物(阿米替林n = 110;氯米帕明n = 109;多塞平n = 102;米安色林n = 28)效果相当。在汉密尔顿抑郁量表上,治疗5 - 6周后的变化,帕罗西汀组显著优于活性对照组。考虑缓解率时也观察到类似优势。帕罗西汀治疗的不良事件发生频率更低、严重程度更低,尤其是抗胆碱能不良事件。帕罗西汀在治疗与抑郁相关的焦虑症状方面有效,且与活性对照药物相比,引起的镇静作用显著更小。帕罗西汀组和活性对照组在总体安全性方面差异不大。然而,有数据表明帕罗西汀的心脏毒性降低,且对自杀念头有有益影响。总体而言,结果表明帕罗西汀是这些较老的抗抑郁药的替代一线治疗药物,在治疗老年患者时应予以考虑。